at-gtx-502
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 13, 2018 (NCT03770572)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BatteninSupplementation
supplementation - CLN3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03770572 | Phase 1/Phase 2 (Phase 2) | Nov 13, 2018 | Amicus Therapeutics, Ohio State University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amicus Therapeutics | For profit | 1 | 0 | 1 | 2018 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1